ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 609,15
-0,69%
Dow Jones
39 127,80
0,04%
DAX
18 155,24
-0,04%
Brent Oil
84,47
0,34%
Bitcoin
60 872,62
-1,52%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Phio Pharmaceuticals Corporation (PHIO)

  7. Phio Pharmaceuticals Corporation (PHIO) Actualités

PHIO

Phio Pharmaceuticals (PHIO)

Phio Pharmaceuticals Corporation
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:PHIO
DateHeureSourceTitreSymboleSociété
28/05/202423h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PHIOPhio Pharmaceuticals Corporation
20/05/202423h03Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:PHIOPhio Pharmaceuticals Corporation
20/05/202422h59Edgar (US Regulatory)Form RW - Registration Withdrawal RequestNASDAQ:PHIOPhio Pharmaceuticals Corporation
17/05/202415h04Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:PHIOPhio Pharmaceuticals Corporation
17/05/202415h00GlobeNewswire Inc.Phio Pharmaceuticals Secures New InvestorNASDAQ:PHIOPhio Pharmaceuticals Corporation
16/05/202414h00GlobeNewswire Inc.Phio Pharmaceuticals Presents This Week at the Society for Investigative Dermatology (SID)NASDAQ:PHIOPhio Pharmaceuticals Corporation
15/05/202419h00GlobeNewswire Inc.Phio Pharmaceuticals Announces Completion of Dosing in First Patient Cohort in PH-762 Phase 1b Dose-Escalation StudyNASDAQ:PHIOPhio Pharmaceuticals Corporation
09/05/202423h25GlobeNewswire Inc.Phio Pharmaceuticals Reports Q1 2024 Results and Provides Business UpdateNASDAQ:PHIOPhio Pharmaceuticals Corporation
09/05/202423h20Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PHIOPhio Pharmaceuticals Corporation
08/05/202423h04Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:PHIOPhio Pharmaceuticals Corporation
08/05/202423h02Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:PHIOPhio Pharmaceuticals Corporation
08/05/202423h00Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:PHIOPhio Pharmaceuticals Corporation
30/04/202413h30GlobeNewswire Inc.Phio Pharmaceuticals Announces Upcoming Presentation at the Annual Meeting of the Society of Clinical Oncology (ASCO)NASDAQ:PHIOPhio Pharmaceuticals Corporation
22/04/202419h10GlobeNewswire Inc.Intratumoral Injection of Phio’s PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cellsNASDAQ:PHIOPhio Pharmaceuticals Corporation
16/04/202413h30GlobeNewswire Inc.Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID)NASDAQ:PHIOPhio Pharmaceuticals Corporation
11/04/202413h30GlobeNewswire Inc.Phio Pharmaceuticals Announces Upcoming Presentation at the 27th Annual Meeting of the American Society of Cell and Gene Therapy (ASCGT)NASDAQ:PHIOPhio Pharmaceuticals Corporation
03/04/202413h30GlobeNewswire Inc.National Spotlight Features Phio’s Innovative RNAi Technology PlatformNASDAQ:PHIOPhio Pharmaceuticals Corporation
02/04/202413h30GlobeNewswire Inc.Phio Pharmaceuticals Reports 2023 Year End Financial Results and Provides Business UpdateNASDAQ:PHIOPhio Pharmaceuticals Corporation
21/03/202412h30GlobeNewswire Inc.Phio Pharmaceuticals Presenting Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological MalignanciesNASDAQ:PHIOPhio Pharmaceuticals Corporation
13/03/202419h00GlobeNewswire Inc.Phio Pharmaceuticals Announces Addition of Clinical Trial Sites at Banner MD Anderson Cancer Center, The George Washington University, and Integrity ResearchNASDAQ:PHIOPhio Pharmaceuticals Corporation
06/03/202416h30GlobeNewswire Inc.Phio Pharmaceuticals Announces Patent Granted by USPTO, Strengthening the Company’s Intellectual Property Position in Treating Aging Skin and Skin DisordersNASDAQ:PHIOPhio Pharmaceuticals Corporation
06/03/202401h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PHIOPhio Pharmaceuticals Corporation
06/02/202416h30Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:PHIOPhio Pharmaceuticals Corporation
31/01/202414h00GlobeNewswire Inc.Phio Pharmaceuticals Announces Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological MalignanciesNASDAQ:PHIOPhio Pharmaceuticals Corporation
28/12/202315h13Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:PHIOPhio Pharmaceuticals Corporation
28/12/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PHIOPhio Pharmaceuticals Corporation
19/12/202322h52Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:PHIOPhio Pharmaceuticals Corporation
19/12/202319h07Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:PHIOPhio Pharmaceuticals Corporation
07/12/202314h00GlobeNewswire Inc.Phio Pharmaceuticals Announces Exercise of Warrants for $2.8 Million Gross ProceedsNASDAQ:PHIOPhio Pharmaceuticals Corporation
09/11/202322h30GlobeNewswire Inc.Phio Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:PHIOPhio Pharmaceuticals Corporation
 Showing the most relevant articles for your search:NASDAQ:PHIO

Dernières Valeurs Consultées

NYSE
NKE
Nike
COIN
BTCUSD
Bitcoin
EU
EN
Bouygues
EU
RI
Pernod Ricard
SPI
SP500
S&P 500
EU
AF
Air FranceKLM
EU
VK
Vallourec
NYSE
JPM
JP Morgan Chase
EU
BEL20
Bel 20
USI
USTECH100
US Tech 100
EU
DG
Vinci
EU
BNP
BNP Paribas
EU
ACA
Credit Agricole
NASDAQ
AMZN
Amazon.com
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés